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Aplastic anemia (AA) occurs when the bone marrow fails to support production of all 
three lineages of blood cells, which are necessary for tissue oxygenation, infection con-
trol, and hemostasis. The etiology of acquired AA is elusive in the vast majority of cases 
but involves exhaustion of hematopoietic stem cells (HSC), which are usually present in 
the bone marrow in a dormant state, and are responsible for lifelong production of all 
cells within the hematopoietic system. This destruction is immune mediated and the role 
of interferons remains incompletely characterized. Interferon gamma (IFNγ) has been 
associated with AA and type I IFNs (alpha and beta) are well documented to cause 
bone marrow aplasia during viral infection. In models of infection and inflammation, 
IFNγ activates HSCs to differentiate and impairs their ability to self-renew, ultimately 
leading to HSC exhaustion. Recent evidence demonstrating that IFNγ also impacts 
the HSC microenvironment or niche, raises new questions regarding how IFNγ impairs 
HSC function in AA. Immune activation can also elicit type I interferons, which may 
exert effects both distinct from and overlapping with IFNγ on HSCs. IFNα/β increase 
HSC proliferation in models of sterile inflammation induced by polyinosinic:polycytidylic 
acid and lead to BM aplasia during viral infection. Moreover, patients being treated with 
IFNα exhibit cytopenias, in part due to BM suppression. Herein, we review the current 
understanding of how interferons contribute to the pathogenesis of acquired AA, and 
we explore additional potential mechanisms by which interferons directly and indirectly 
impair HSCs. A comprehensive understanding of how interferons impact hematopoiesis 
is necessary in order to identify novel therapeutic approaches for treating AA patients.
Keywords: hematopoietic stem cells, interferon-gamma, interferon type i, aplastic anemia, bone marrow 
microenvironment, macrophages, T lymphocytes
iNTRODUCTiON
The concept of aplastic anemia (AA) was first introduced by Paul Ehrlich in 1888 and describes 
patients who fail to form blood cells from all three lineages, in association with decreased or absent 
bone marrow precursor cells. Although there are many known etiologies, the cause of AA is generally 
difficult to determine in an individual patient and in the vast majority of cases no causal etiology 
is found (1). The focus of the current review is on the role of interferons in the pathophysiology 
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of this bone marrow failure (BMF) syndrome. The association 
of disease with expansion of autoreactive T lymphocytes (2, 3) 
and responsiveness of disease to immunosuppressive therapies, 
including antithymocyte globulin (ATG) and cyclosporine (4), 
demonstrate the immune-mediated nature of acquired AA. 
Although the precise cause of acquired AA is unknown, links 
to radiation, chemical exposure, and infection have been made. 
Gene polymorphisms that alter cytokine production or stability, 
particularly interferon gamma [IFNγ; Ref. (5)] provide additional 
evidence that dysregulated inflammatory responses are an essen-
tial driving force in the BMF seen in acquired AA. Mechanisms 
underlying the loss of hematopoietic stem cells (HSCs) during 
BMF include increased apoptosis and enhanced stem cell activity 
resulting in exhaustion. Here, we focus on the role(s) of inter-
ferons in the pathogenesis of BMF, and highlight new questions 
and avenues of research that may reveal therapies for targeted 
treatment of acquired BMF.
Regulation of HSC Function: intrinsic and 
Niche-Mediated Mechanisms
Quiescence preserves the self-renewal capacity and, therefore, 
the long-term function of HSCs. The regulators of this dormant 
state include intrinsic pathways as well as soluble and contact- 
dependent factors present in the niche microenvironment 
[reviewed in Ref. (6)]. Dysregulated HSC cycling may contribute 
to AA by enhancing differentiation over self-renewal or by sensi-
tizing HSCs to apoptosis (7–10). Interferons have been implicated 
in both driving proliferation (11) and impairing proliferation of 
primitive hematopoietic stem and progenitor cells (HSPCs) (12), 
and sensitizing cells to apoptosis (13), thus supporting the notion 
that IFNs directly impair hematopoiesis by compromising stem 
cell function.
An altered microenvironment may also contribute to the 
pathogenesis of AA. Analysis of BM mesenchymal stromal cells 
(MSCs) derived from AA patients revealed reduced proliferative 
capacity and adherence, and a propensity to differentiate into adi-
pocytes at the expense of osteoblasts (OBs) (14, 15). Considering 
the essential survival and dormancy-enforcing cues provided 
by niche cells, it will be important to investigate more fully the 
defects in stromal cells in acquired AA, and the impact of IFNs, 
either directly or indirectly, on such cells.
interferons in Acquired AA
The observation that patients with acquired AA exhibit increased 
levels of circulating IFNγ was made over 30 years ago (16). The 
presence of T cells containing intracellular IFNγ and positive for 
the prototypical Th1 transcription factor Tbet is an indicator of 
disease (17), and reduced frequencies of IFNγ positive T cells 
correlates with responsiveness to immunosuppressive therapy 
(4), suggesting that Th1 cells contribute to disease pathogenesis. 
Attempts to understand how IFNγ-mediated disease pathogenesis 
revealed that overexpression of IFNγ in vitro impairs long-term 
culture initiating cells LT-CIC (18), consistent with observations 
that neutralizing IFNγ in cultures derived from AA patients 
resulted in improved colony formation (16). Moreover, a poly-
morphism that results in enhanced stability of IFNγ transcripts is 
strongly associated with the risk of developing AA (5). However, 
the precise mechanisms whereby IFNγ drives BMF in  vivo are 
still unclear and may involve multiple overlapping pathways and 
multiple cell types.
Type I IFNs (IFNα/β) are key regulators of innate and adaptive 
immunity. Although not directly implicated in AA pathogenesis, 
type I IFNs mediate host responses to most infections and contrib-
ute to autoimmunity in systemic lupus erythematosus [recently 
reviewed in Ref. (19)] and potentially in diabetes mellitus, Sjogren’s 
syndrome, autoimmune myositis, and rheumatoid arthritis (20, 
21). Pegylated IFNα 2a (PEG-IFNα2a) is the standard of care in 
hepatitis C virus (HCV) patients, but is also a treatment option for 
melanoma (22), hairy cell leukemia (23), and multiple sclerosis 
(24–26). Type I IFN therapy is not well tolerated by all patients, 
however, and hematologic side effects are closely monitored. 
HCV patients receiving both PEG-IFNα2a and the nucleoside 
analog ribavirin are prone to hemolytic anemia due to ribavirin 
processing in erythrocytes as well as PEG-IFNα2a-mediated BM 
suppression (27, 28). Rarely, type I IFN therapies have also been 
linked to persistent BM suppression and the development of AA 
(24, 29, 30). BM suppression appears not to require exogenous 
or supraphysiologic levels of IFNα/β, as anemia and BM failure 
have also been associated with physiologic type I IFN responses 
to chronic viral infection (31). Of particular relevance to AA, the 
impact of type I IFNs on hematopoiesis is often not immediately 
suppressive, but requires secondary stress, such as exposure 
to subsequent IFNγ during the pathogenesis of lymphocytic 
choriomeningitis virus (LCMV) infection (12). Herein, we will 
discuss the potential for direct and niche-mediated type I IFN 
stimulation to impair HSCs and contribute to acquired AA.
Bone Marrow Failure induced by infection
Bone marrow suppression has been observed subsequent to a 
number of viral infections, including parvovirus (32, 33), human 
immunodeficiency virus [HIV; Ref. (34)], viral hepatitis (35), 
Epstein–Barr virus (36), and influenza (37), among others. The 
ability of viral infections to suppress the BM may be due to both 
the ability of viruses to actively infect cells of the hematopoietic 
system and the host response to the virus, likely involving 
production of interferons and other pro-inflammatory factors. 
BM suppression and severe cytopenias are also common after 
exposure to tick bites, and are associated with the rickettsial 
pathogens Ehrlichia chaffeensis and Anaplasma phagocytophilum 
(38). Though transient, cytopenias are often severe, and infection 
requires antibiotic treatment (39). Human monocytic ehrlichio-
sis has been associated with bone marrow hypoplasia (40) and 
hemophagocytic lymphohistiocytosis [HLH; (41)], and murine 
models implicate interferon responses in mediating bone marrow 
suppression in rickettsial infections (42–44).
Models to Study Human AA
Bone marrow failure pathogenesis was first modeled in mice 
using exposure to toxins, instigated by the association of benzene 
exposure with human disease (45). Observation that AA is a 
result of immune-mediated pathology prompted the develop-
ment of donor lymphocyte infusion models relying on the 
adoptive transfer of lymph node or spleen-derived lymphocytes 
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from histocompatibility mismatched strains of mice (46). This 
model recapitulates many observations in human AA patients 
as protection can be achieved with immunosuppressive treat-
ment and abrogation of IFNγ (47, 48). A technical hurdle of the 
infusion-based model is that the use of F1 recipients precludes 
analysis of genetically targeted mice. Thus, it has been difficult 
to evaluate direct and indirect roles of specific cytokines on 
hematopoietic versus stromal cells. However, it has allowed a 
deeper understanding of T cell intrinsic mechanisms necessary 
for initiation of disease, including Notch signaling (49) and 
transcriptional regulators of Tbet (50). To model human patients 
carrying a mutation that renders a higher risk for developing 
AA, a mutation was introduced to the 3′ untranslated region of 
the Ifng gene, stabilizing IFNγ transcripts (51). Termed “ARE-
delete,” this mouse model reproduces many features of human 
disease and is not associated with autoreactive T cells, suggesting 
that elevated IFNγ, independent of activated T cells, can drive 
disease by impairing progenitor cell function (51). In addition, 
a number of insights into bone marrow suppression have come 
from studying bacterial and viral pathogens. In ehrlichiosis, 
HSC loss requires IFNγ sensing by macrophages, demonstrating 
that interferon signaling reduces the HSC supportive capacity 
of niche cells during infection-induced BM suppression (42). 
In LCMV, phenotypic HSCs are reduced early in the course of 
infection, independent of IFNγ and likely through the actions of 
type I IFNs (12, 31). Together, the observations made in murine 
infection models and in a subset of patients undergoing PEG-
IFNα2a treatment provide additional evidence that interferons 
impair HSCs, likely via multiple direct and niche-mediated 
mechanisms.
MeCHANiSMS OF iFNγ-MeDiATeD AA
HSC-intrinsic impact of iFNγ
The negative impact of IFNγ on hematopoiesis is well docu-
mented [reviewed in Ref. (52)], but what is the evidence that there 
is a direct impact of IFNγ on the most primitive HSCs? HSC loss 
can occur via impaired self-renewal, increased differentiation, 
or induction of cell death, which may be results of both direct 
and/or indirect effects of IFNγ. While some studies suggest that 
IFNγ has an antiproliferative effect on HSCs (12, 53), evidence 
also suggests that IFNγ signaling promotes proliferation, and 
subsequent exhaustion of HSCs (11, 54). During infection with 
Mycobacterium avium or LCMV, IFNγ increased HSC prolifera-
tion and led to a reduction in transplantable myeloid potential 
(11, 55). Moreover, HSCs from a microenvironment deficient in 
IFNγ have more robust long-term potential, whereas excessive 
IFNγ signaling reduces transplantable HSPC activity (54, 56), 
further suggesting that tonic IFNγ signaling limits HSC function, 
perhaps through inducing proliferation. The discordant results 
with respect to whether IFNγ induces or suppresses proliferation 
is further confounded by the complex interaction with other 
cytokines, as IFNγ can augment the expansion of myelogenous 
leukemia cells when it signals in concert with IL-3, but can sup-
press proliferation in cells lacking IL-3 stimulation (57). In addi-
tion, TNFα stimulation is necessary for maximal IFNγ-induced 
suppression and proliferation of leukemia cell cultures (57), 
further emphasizing the potential for IFNγ to elicit distinct and 
even opposing effects dependent on the local cytokine milieu.
Stem cell proliferation can result in the generation of more 
stem cells (self-renewal) or more committed progenitors (dif-
ferentiation) and IFNγ has also been implicated in impeding 
self-renewing divisions (Figure 1a) (12, 58). Notably, IFNγ was 
shown to directly reduce HSC self-renewal during recovery from 
viral infection where robust type I IFNs had ablated the HSC pool 
(12), suggesting that type I IFNs may potentiate the suppressive 
impact of IFNγ on hematopoiesis during viral infection. These 
data highlight the importance of the cellular and cytokine context 
in the impact of single cytokines. Whereas IFNγ may not impede 
self-renewal in the steady state, prior exposure to type I IFNs may 
sensitize HSCs to the effects of IFNγ; at the same time, the induc-
tion of cellular stress by type I IFN-induced HSC cycling could 
enhance the potential for IFNγ to provoke HSC apoptosis during 
immune-mediated BM failure (59, 60).
Hematopoietic stem cells require a variety of inputs from 
growth factors, chemokines, G protein-coupled receptors, 
and cytokines to maintain their dormant status, location, and 
capacity to self-renew. An intriguing role for IFNγ in limiting 
responsiveness to the growth factor thrombopoietin (TPO) via 
the increase in suppressor of cytokine signaling (SOCS1) (12) 
(Figure  1b) illustrates yet another direct mechanism whereby 
IFNγ can impede HSC function. Support for the role of TPO in 
HSC function comes from the promising clinical data using a 
TPO receptor (c-Mpl) agonist, Eltrombopag (61). When given 
in combination with immunosuppressive drugs, it can provide 
tri-lineage recovery in patients refractory to traditional therapies 
(62). Though precise mechanisms of Eltrombopag function have 
not yet been elucidated, one possibility is that the drug works by 
overcoming a direct impact of IFNγ on suppressing TPO signal-
ing in HSCs.
Interferon gamma is elicited by many microbial infections 
and plays a critical role in host defense by sensitizing cells to 
undergo apoptosis, thus impeding pathogen growth (63, 64). 
IFNγ can induce apoptosis by increasing the expression of Fas on 
cells subsequently targeted by Fas ligand-expressing cells, such as 
T lymphocytes (60). Evidence that HSCs express Fas in response 
to IFNγ (Figure 1c) suggests Fas-mediated destruction of HSCs 
contributes to their loss in AA (60). It is important, however, to 
consider the question of HSC sensitivity to IFNγ. Indeed, whereas 
some cell types respond very rapidly to IFNγ in  vitro, such as 
macrophages, HSCs exhibit a much more subtle response, as 
measured by activation of STAT1 (42). This may indicate that the 
ability of HSCs to respond to IFNγ in vivo may be concentration 
dependent, and it suggests that HSCs are likely not first respond-
ers to IFNγ during an initial exposure. Under prolonged condi-
tions of chronic exposure, however, HSCs may become direct 
targets. Thus, there are temporal considerations when evaluating 
the direct impact of IFNγ on HSCs under different inflammatory 
conditions.
impact of iFNγ on Progenitors
The idea that HSC activation can be achieved directly or as a 
result of demand implies that HSC loss may result from increased 
progenitor cell activity or loss. Several lines of evidence support 
FiGURe 1 | The actions of iFNγ directly on HSCs and on cells of the microenvironment can result in HSC impairment in acquired aplastic anemia. 
This figure summarizes key direct (A) and indirect (B) impacts of IFNγ on HSCs. The inset on the left depicts HSC-intrinsic effects of IFNγ, including STAT1-mediated 
hematopoietic differentiation programs (a), restriction of thrombopoietin – c-Mpl signaling by SOCS1 (b), and promotion of Fas expression (c). The inset on the  
right depicts cell types in the bone marrow microenvironment that are capable of regulating HSCs in an IFNγ-dependent manner include Tbet+ T lymphocytes, 
macrophages (MΦs), mesenchymal stromal cells, and hematopoietic progenitors. Known molecular mechanisms by which these cell types engage in IFNγ-dependent 
HSC regulation include: increased demand for progenitor cell differentiation to replenish downstream hematopoietic compartments (d), expression of death receptor 
ligands FasL and TNFα by T lymphocytes (e), propagation of MΦ-derived inflammatory signals (f) and potential impairment to MΦ-dependent regulation of HSC 
quiescence (g), and the production of further myelopoiesis-promoting factors by BM stromal cells (h).
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a direct role for IFNγ in impacting murine progenitor cells in 
the context of infection (43, 65). IFNγ promotes the emergence 
of a phenotypically unique, hybrid progenitor population that 
expresses the IL-7 receptor and has both myeloid and lymphoid 
potential in  vitro, but has primarily myeloid potential in  vivo. 
Similarly, an intrinsic requirement for IFNγ was found to occur 
during bacterial infection, directing the production and terminal 
differentiation of myeloid cells (43). In a model of sterile inflam-
mation, via adoptive transfer of activated effector T lymphocytes, 
IFNγ acted directly on progenitors, but not HSCs (66). The ability 
of IFNγ to act on downstream progenitors to drive proliferation, 
however, may indirectly call HSCs from a dormant state, which 
may explain observations suggesting that IFNγ acts directly on 
HSCs (Figure 1d).
indirect or Niche-Mediated effects  
of iFNγ on HSC Function
T Lymphocytes
Although T cells are the cellular source of IFNγ that drives 
AA pathology, T cells also sense and respond to IFNγ. The 
effects of IFNγ on T cells include promotion of Th1 CD4+  
T cell differentiation, enhancement of CD8+ T cell response, and 
subversion of IFNγ-mediated apoptosis via the downregulation 
of IFNγ receptor (67–69). IFNγ also primes activated T cells to 
secrete more abundant TNFα and RANKL (70, 71), inflamma-
tory cytokines capable of inducing hematopoietic cell death and 
further inflammation. Additionally, T cells derived from AA 
patients show elevated Fas ligand expression (72) (Figure  1e), 
which is IFNγ dependent in murine lymphocyte infusion models 
of AA (60). Thus, it is likely that IFNγ acts to expand and preserve 
pathologic T cells in the BM during AA.
A population of T regulatory cells (Tregs) reside in the BM 
at homeostasis [reviewed in Ref. (73)] and establishes HSC-
protective niches during transplantation and reconstitution (74). 
The direct HSC supportive capacity of Tregs in AA has not yet 
been evaluated, but Tregs derived from AA patients are reduced 
in number and inhibitory capacity, and show enhanced produc-
tion of cytokines, including IFNγ (75, 76), suggesting that they 
may further contribute to immunopathology in the BM microen-
vironment. In Tregs, SOCS1 signaling controls IFNγ production 
(77) and defects in SOCS1 activity are thought to underlie auto-
immunity and susceptibility to endotoxemia [reviewed in Ref. 
(78)]. Therefore, ex vivo expansion and treatment of autologous 
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Tregs with small molecule SOCS1 mimetics may prove a promis-
ing therapeutic strategy for AA patients who do not respond well 
to conventional immunosuppression (76, 79).
Osteoclasts
Osteoclasts (OCLs) are bone-resorbing myeloid cells that are 
both directly and indirectly sensitive to IFNγ. Osteoclastogenesis 
requires the sensing of M-CSF and RANKL by myeloid precur-
sors (80). Direct IFNγ sensing by myeloid precursors attenuates 
RANK signaling (81), but systemic IFNγ responses are associ-
ated with enhanced bone resorption due to the OCL-promoting 
impact of TNFα and RANKL (70, 71). Since IFNγ and TNFα 
levels are elevated in AA patients (82, 83), accelerated osteoclas-
tic differentiation of myeloid precursors may occur early in AA 
pathogenesis. Indeed, low bone mineral density and osteopo-
rosis are prevalent in individuals with the inherited BM failure 
condition Shwachman–Diamond syndrome (84) and have been 
observed in Fanconi anemia patients following BM transplanta-
tion (85). Whether inflammatory bone loss contributes to hema-
tologic impairment in AA is currently unknown. OCLs and bone 
resorption have been found to reduce HSPC support in murine 
models, however, and are associated with HSPC mobilization (86, 
87). The actions of bone-forming OBs and bone-resorbing OCLs 
are regulated primarily by the endocrine system (88). Since the 
responses of BM T cells to circulating hormones stimulates bone 
formation and short-term HSC expansion through Wnt signaling 
(89), T cell-based therapies warrant further investigation for their 
potential not only to reduce immunopathology, as mentioned 
above, but also to regenerate HSPCs and BM microenvironmen-
tal function in AA.
Macrophages
The BM microenvironment contains a heterogeneous population 
of tissue-resident macrophages (MΦs) that sense and respond 
to IFNγ [reviewed in Ref. (90)]. IFNγ stimulates MΦ cytokine 
production (Figure 1f) and antigen presentation (91), therefore, 
it stands to reason that MΦs may contribute to IFNγ-driven 
AA pathogenesis. We have previously established that MΦs in 
general, and IFNγ-stimulated MΦs in particular, reduce the pool 
of HSCs in a model of human monocytic ehrlichiosis, which 
causes transient BM suppression (42). Intriguingly, one of the few 
hematopoietic cell types found to be maintained in AA BM is the 
CD169+ MΦ (92). Tissue-resident MΦ populations, including 
BM-resident MΦs, are thought to be embryonically derived and 
maintained via self-renewal, rather than derived from HSC dif-
ferentiation (93) [and recently reviewed in Ref. (94)]. This would 
support the idea that the maintenance of MΦs may not require 
an intact HSPC pool, thus explaining their persistence in the BM 
of patients with AA.
As antigen-presenting cells, MΦs are relatively weak (95), 
thus, it is unlikely that MΦs drive AA pathogenesis by activating 
T cells directly. Mice deficient in myeloid lineage cells are resistant 
to severe AA induction (96), however, suggesting that MΦs are 
indispensable in AA pathogenesis. While further investigation is 
necessary to determine if MΦ number and function correlates 
with AA severity, it can be envisioned that MΦs play a pathologic 
role in AA via several mechanisms. Since HSPCs and resident 
MΦs interact within the BM microenvironment (97–99), it is pos-
sible that IFNγ stimulates pathologic HSPC engulfment by MΦs 
in AA. In fact, IFNγ is associated with hemophagocytosis-induced 
anemia (100), and MΦs have been implicated in the pathogenesis 
of human hemophagocytic disorders, such as juvenile idiopathic 
rheumatoid arthritis and lymphohistiocytosis (101, 102), as well 
as platelet clearance in immune-mediated thrombocytopenia 
(103). Alternatively, MΦs may contribute to HSPC loss in AA 
by regulating, either directly or indirectly, HSPC proliferation 
or differentiation. Quiescent HSCs are called to proliferate and 
differentiate in response to demand for mature progeny, such as 
myeloid cells or platelets (104, 105), but must reenter quiescence 
in order to avoid replication stress and ensure lifelong mainte-
nance. MΦs have been implicated in maintaining long-term HSC 
quiescence, or dormancy, through the production of PGE2 and 
the maintenance of the quiescence-promoting tetraspanin CD82 
on the surface of HSCs via Duffy antigen receptor (DARC) on 
MΦs (98, 99) (Figure 1g); however, functional changes to this 
cell–cell interaction upon inflammation have only just begun 
to be investigated. In conditions of inflammation and infection, 
MΦs may suppress dormancy as a way to enlist HSCs in demand-
adapted hematopoiesis. In murine ehrlichiosis, IFNγ is required 
for BM-resident MΦ maintenance, and is also essential for the 
infection-dependent loss of HSCs. Upon MΦ depletion, HSCs 
proliferate, under both steady-state (98) and infectious condi-
tions (42). McCabe et  al. found that these HSCs subsequently 
reenter quiescence, resulting in HSC pool expansion. Thus, under 
infection states, and perhaps in AA, IFNγ-stimulated MΦs drive 
HSC loss. This may occur via inhibition of HSC proliferation and 
demand-adapted hematopoiesis or alternatively, via increased 
differentiating proliferation, at the expense of self-renewal, cul-
minating in HSC exhaustion.
Hematopoietic stem cells are motile within the BM of 
infected mice (106), suggesting that HSC engagement with the 
niche may be important for demand-adapted hematopoiesis. 
Since MΦs support the expression of HSPC retention factors by 
endosteal cells (97), MΦs may render HSCs more susceptible to 
T cell-mediated killing, and less capable of migration to micro-
environments that support cell cycle entry and differentiation. At 
homeostasis, a population of endosteal MΦs, termed osteomacs, 
is reported to mediate osteoblastic NF-κB signaling, maintenance 
of bone-lining OBs, and hematopoietic progenitor cell retention 
in the BM (97, 107). Whether MΦs stimulated with IFNγ or other 
inflammatory cytokines, as in AA, drive osteoblastic dysfunction 
(see below), remains an open question. Since BM MΦs persist in 
AA patients, in spite of reductions in nearly all other BMC popu-
lations (92), and since MΦs potently respond to IFNγ, studies 
focused on the impact of MΦs in AA pathogenesis are warranted.
Mesenchymal Stromal Cells
Mesenchymal stromal cells respond to inflammatory signals, 
including IFNγ, to regulate the differentiation of HSCs and the 
mobilization of their progeny (66, 108). Cytotoxic CD8+ T cell-
derived IFNγ was recently found to stimulate IL-6 production 
by BM MSCs, thus identifying a niche-mediated mechanism 
by which IFNγ stimulates myeloid transcriptional programs in 
hematopoietic progenitors (Figure  1h) (66). Consistent with 
TABLe 1 | impact of acute and chronic polyi:C-induced inflammation on 
HSCs and HSPCs.
HSCs Hematopoietic 
progenitors
Acute • Reduced in frequency but not changed 
in number (13)
• Cell cycle entry (13, 59)
• Increased redox stress, accumulation 
of DNA double-strand breaks, and 
engagement of Fanconi anemia DNA 
repair pathway (59)
• Increased translation of megakaryocyte- 
lineage proteins (104)
• Enhanced death in vitro (59)
• Increased myeloid 
(13) and CD41hi stem-
like megakaryocyte 
progenitors (104)
• No change in 
Lineage− c-Kit+ 
cell cycling, DNA 
damage, or colony 
formation (59)
Chronic • Reduced in frequency, trend toward 
reduction in number (13)
• Loss of function in response to 
chemotherapeutic injury, transplantation, 
and in vitro expansion (13, 59, 128)
• Transiently reduced cyclin-dependent 
kinase inhibitor and quiescence- 
enforcing gene expression (13)
• Activation of PI3K/mTOR signaling (129) 
and increased m-Myc protein levels (130)
• Caspase 3 activation (13)
• Myeloid bias in transplantation (59)
• Transiently increased 
Lineage− c-Kit+ cell 
pool (13)
• Exhaustion of stem-
like megakaryocyte 
progenitor cell 
function (104)
Note that polyI:C was obtained from InvivoGen (59, 128, 130), GE Life Sciences (131, 
132), and Invitrogen (104).
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these observations, BM stromal cells derived from AA patients 
and from a murine model of AA show elevated Il6 expression 
(15, 109). Since there is a higher prevalence among AA patients 
for an Il6 gene polymorphism conferring IL-6 hypersecretion 
(83), it is currently unclear whether elevated IL-6 in AA is IFNγ-
dependent. IL-17 is increased in the BM plasma of AA patients 
and more potently stimulates IL-6 secretion by MΦs derived 
from AA BM than from healthy controls (110), suggesting that 
inflammation in AA primes the responses of MSCs and other 
cell types to amplify local cytokine production. Since MSCs exist 
in close proximity to HSCs, and can greatly influence HSC fate, 
the impact of IFNγ on MSCs in AA is a key unanswered question 
in the field.
Adult BM MSCs are rare but exhibit heterogeneity with 
respect to their developmental origin, localization in the BM, 
and contribution to bone formation and HSPC regulation 
(111–114). This heterogeneity, coupled with the need for genetic 
reporter strains to identify and delineate MSC populations, has 
hindered investigation of BM MSCs in disease models, including 
in lymphocyte infusion-based AA models where IFNγ is known 
to be pathogenic. MSC dysfunction may contribute to BM failure, 
as MSCs possess immunoregulatory potential [reviewed in Ref. 
(115–117)] and are critical HSC-support cells. With regard to 
HSC niche function, peri-arteriolar MSCs enforce quiescence 
and are required for long-term HSC function (118). When the 
niche is activated, such as through hormonal stimulation, MSCs 
increase in number and mediate expansion of the HSC pool (112). 
Although adherent BM stromal cells, enriched in MSCs, show 
normal surface marker expression in AA patients, these cells fail 
to expand readily in culture, undergo greater apoptosis, and are 
impaired in osteogenic but enhanced in adipogenic differentia-
tion, relative to normal controls (14, 15, 119). Unlike osteolineage 
cells, which support HSPCs and B lymphopoiesis (120, 121), BM 
adipocytes are detrimental to HSCs (122). MSC differentiation 
into either adipogenic or osteogenic progenitors is controlled 
by cell intrinsic and extrinsic mechanisms (123, 124). Systemic 
inflammation, as induced by high-fat diet, was recently linked to 
PPARγ activation in MSCs and resultant adipogenesis, concomi-
tant with a reduction in HSPC support by the microenvironment 
(125). Severe AA, therefore, could erode BM microenvironmental 
function and HSC niches by a similar mechanism.
Elevated IFNγ may impact MSCs in AA via a number of dis-
tinct or overlapping mechanisms. T cell-mediated MSC killing, 
IFNγ-induced MSC dysfunction, or bystander effects mediated 
by neighboring BM cell types all potentially contribute to AA 
pathogenesis. Although MΦs are dispensable for the mainte-
nance of BM MSCs at homeostasis, they regulate MSC function 
by promoting MSC expression of the niche-retention factors 
Cxcl12, Angpt1, Kitl, and Vcam1 (126). Moreover, MΦs support 
the presence of mature OBs along the endosteum at homeostasis 
(97), potentially by stimulating NF-κB-mediated osteoblastic 
differentiation of MSCs or immature OBs (107). These data 
indicate that in an otherwise unperturbed system, MΦs promote 
the survival and/or osteolineage differentiation of bone-lining 
OBs. Thus, the potential for MΦs to dysregulate MSCs resulting 
in HSC niche destruction in AA and other disease states warrants 
investigation.
MeCHANiSMS OF iFNα/β-MeDiATeD 
HSPC iMPAiRMeNT
HSC-intrinsic impact of Type i iFNs
Early observations made in LCMV-infected mice (31), and in 
IFNα-treated HSPC cultures (127), led to the conclusion that type 
I IFNs suppress progenitor cell proliferation and differentiation. 
Indeed, IFNα induces HSPC expression of cell cycle inhibitors 
in  vitro (13). In vivo, however, the impact of IFNα/β differs. 
Acute administration of the double-stranded RNA mimetic 
polyinosinic:polycytidylic acid (polyI:C) causes rapid, IFNα 
receptor (IFNαR)-dependent HSC cycling (13, 128), and has 
been the model of choice for studying type I IFN-mediated HSPC 
activation (see Table 1 for a summary of relevant findings). The 
impact of polyI:C-induced sterile inflammation varies depend-
ing upon the duration of stimulation and the precise HSC subset 
analyzed, but acute stimulation is sufficient to decrease HSC 
expression of cyclin-dependent kinase inhibitors and quiescence-
enforcing transcriptional programs, including FoxO3a, Notch, 
and TGFβ (13).
The function of type I IFNs in the context of physiologic 
induction, such as infection, may provide insight into pathogenic 
role(s) of type I IFNs in AA. Somewhat paradoxically given 
the BM suppressive impact of IFNα in viral infection, the type 
I IFN response to opportunistic Pneumocystis lung infection is 
protective in Rag−/− mice (133). Since these mice lack all B and 
T lymphocytes, immunity depends entirely upon myeloid cells, 
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which undergo greater apoptosis in the absence of type I IFNs 
(134). In Pneumocystis-infected Rag competent mice, IL-10 and 
IL-27 production by B lymphocytes is protective, and correlates 
with enhanced myelopoiesis (135). Thus, in the absence of lym-
phocytes, and the cytokines they produce, type I IFNs provide a 
survival signal for myeloid cells. These findings further support 
the notion that the complex cytokine milieu greatly impacts the 
outcome of IFN signaling on HSC function.
At homeostasis, HSC quiescence protects against replication 
stress and genomic instability. Long-term label retaining studies 
demonstrate that ~1% of phenotypic HSCs cycle per day (136) 
and that a subset of multipotent progenitors is maintained in 
a similarly dormant state (137). PolyI:C increases HSC cycling 
six- to sevenfold for up to 3 days, leading to the accumulation 
of reactive oxygen species and DNA damage in remaining HSCs 
(59). DNA damage itself induces type I IFN-mediated stem cell 
senescence (138), in addition to the activation of cellular check-
points and tumor suppressor genes [recently reviewed in Ref. 
(139)]. Additionally, type I IFNs transcriptionally regulate p53 
(140), through the interferon-stimulated signaling complex ISGF3 
(141, 142). Therefore, type I IFNs have the capacity to induce both 
proliferation as well as DNA damage-induced p53 signaling, thus 
priming HSCs to undergo apoptosis upon cellular stress, such as 
in  vitro culture (13). These findings, therefore, implicate type I 
IFNs in the induction of replication and oxidative stress in HSCs.
In vivo, repeated IFNα/β stimulation or uncontrolled type I 
IFN signaling is detrimental to HSCs exposed to chemotherapeu-
tic injury or transplantation (13, 128, 143), likely by promoting 
cell cycle entry and heightened sensitivity to cellular stress. While 
this may be detrimental in some cases, complete molecular remis-
sion has been observed in several cases of chronic myelogenous 
leukemia (CML) where IFNα pre-treatment was followed by 
imatinib mesylate (144), suggesting that IFNα may induce CML 
stem cell exit from dormancy and subsequent sensitization to 
growth factor withdrawal. The sensitizing effect of type I IFNs 
on stem cells persists, as HSCs transplanted from mice 2 weeks 
after polyI:C stimulation remained functionally impaired in their 
repopulating capacity (13). Therefore, it is reasonable to expect 
that increases in endogenous IFNα/β during viral infections 
or chronic administration of type I IFNs may have long-term 
impacts on HSC response to subsequent inflammatory stimuli. 
Such a mechanism is consistent with HSC impairment and BM 
suppression during LCMV infection, which elicits initial IFNα/β 
followed by subsequent IFNγ (12, 31, 145). Further studies are 
necessary, however, to determine if apoptosis is the predominant 
mechanism by which HSCs are depleted upon type I IFN sensi-
tization, or if IFNα/β also sensitizes HSCs to senescence, or to 
non-apoptotic cell death.
In addition to HSC proliferation and apoptotic sensitization, 
type I IFNs influence HSPC differentiation. IFNα/β increases the 
synthesis of proteins required for rapid hematopoietic progenitor 
cell differentiation in response to inflammation and demand. This 
occurs via a post-transcriptional mechanism, the targets of which 
include the c-Myc transcription factor (130), and megakaryocyte 
lineage proteins (104). Expression of the megakaryocyte lineage 
gene von Willebrand factor and the alphaIIb integrin protein CD41 
have previously been attributed to the most primitive HSCs (146, 
147), but Haas et al. identified the IFNαR-dependent emergence of 
highly proliferative, CD41hi megakaryocyte-restricted progenitor 
cells within the phenotypic HSC pool upon stimulation of mice 
with polyI:C, TNFα, or lipopolysaccharide (104). Since CD41 
was not interrogated in previous studies, it is unclear to what 
extent megakaryocyte-primed progenitor cells contributed to the 
observed effects of type I IFNs on HSPC proliferation, apoptotic 
sensitization, and multilineage repopulation (13, 59, 128).
Hematopoietic stem cell metabolism is exquisitely regulated 
to protect against metabolic stress and to regulate the nature of 
cell division upon entry into the cell cycle (148), such as occurs 
upon type I IFN stimulation. One mechanism by which HSC 
metabolism is regulated is through autophagy and the Foxo 
family of transcription factors (149). FOXO3A, in particular, has 
been implicated in the activation of autophagy gene expression 
programs in HSCs that are essential for HSC survival upon 
cytokine withdrawal or calorie restriction-induced stress (150). 
Additionally, Warr et al. found that HSCs derived from aged mice 
had greater autophagic flux and were more reliant on autophagy 
for colony formation in  vitro. Sterile type I IFN stimulation 
reduces FOXO3A expression and signaling activity in HSPC 
subsets (13, 104). Moreover, infection-induced type I IFNs are 
linked to reduced autophagic flux in the liver (151). The impact 
of type I IFNs on HSC autophagy has not yet been assessed, but 
autophagic suppression was recently identified in CD34+ BM cells 
from AA patients, and persisted even upon amelioration of AA 
symptoms (152). Therefore autophagy inhibition could represent 
an additional mechanism by which interferon signaling impairs 
HSC stress responses and exacerbates pathology in AA.
indirect or Niche-Mediated effects  
of iFNα/β on HSC Function
T Lymphocytes
In AA pathogenesis, oligoclonally expanded CD8+ T cells 
infiltrate the BM and produce damaging, pro-inflammatory 
cytokines, including IFNγ (153). Type I IFNs regulate T cell 
production of IFNγ in a highly context-dependent manner, 
whereby type I IFNs are associated with enhanced IFNγ dur-
ing extracellular bacterial infection (154), but with reduced 
IFNγ in response to intracellular pathogens (155–157). 
Type I IFNs may also contribute to the activation and expansion 
of pathologic T cells in AA as IFNα/β increases the survival of 
antigen-specific CD8+ T cell clones, as well as the generation 
and cytolytic activity of memory T cells (158, 159). Indeed, the 
blood and BM of AA patients show increased effector memory 
T cells (160), which may be derived from a newly identified class 
of progenitors termed memory stem T cells (161, 162). Since 
type I IFNs drive cell cycle entry and differentiation of other 
HSPC subsets (13, 104), they may also impact the development of 
CD8+ memory T cells from memory stem T cells and contribute 
to the etiology of infection-induced and iatrogenic BM failure 
through the modulation of T cell populations.
Macrophages
During infection, MΦs are stimulated concurrently with IFNs 
and TNFα and amplify inflammation through the production 
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of additional IFNα/β and TNFα (163). Like IFNγ, TNFα is 
highly pathogenic in AA (164–166) and may engage in cross-
talk with type I IFN signaling. TNFα levels correlate with the 
extent of cytopenia (165), and TNFα neutralization improves 
the colony-forming activity of AA patient BM (164). In addition 
to elevated circulating TNFα, TNF receptor 1 and 2 (TNFR1/
TNFR2) expression is increased on hematopoietic progenitors 
derived from AA patients relative to healthy controls (165). 
TNFR2 ligation initiates inflammatory signaling, whereas 
TNFR1 drives the assembly of cytoplasmic cell death signaling 
complexes [reviewed in Ref. (167)]. A number of mechanisms, 
including caspase activity and ubiquitination of TNF receptor 
interacting protein kinase 1 (RIPK1), promote immuno-
logically silent apoptosis when TNFR2 is activated [reviewed in 
Ref. (168)]. If caspase activity is limited, however, RIPK1–RIPK3 
interactions mediate RIPK3-dependent phosphorylation of the 
pseudokinase MLKL. Phosphorylated MLKL then translocates 
to cellular membranes where its pore-forming action leads to 
cell lysis and the release of intracellular contents in a process 
known as necroptosis.
MΦs in Salmonella typhimurium-infected mice were the first 
cell type found to undergo IFNαR- and RIP1-dependent necrop-
tosis in  vivo (169). Subsequent studies have found an absolute 
requirement for IFNα/β priming in the death of MΦs by necrop-
tosis (163, 170). Thus, the combinatorial impact of TNFα and type 
I IFNs has the potential to drive MΦs necroptosis in autoimmune 
diseases, such as severe AA. BM-resident MΦs are abundant 
HSPC–niche cells [recently reviewed in Ref. (90)], therefore, 
even a low rate of MΦ necroptosis has the potential to exacer-
bate immunopathology through release of damage- associated 
molecular patterns from the lytic cells, and/or impairment of 
the mononuclear phagocyte system responsible for clearing dead 
and dying cells, including apoptotic HSPCs. Further research is 
also needed to discern whether myeloid progenitors, and HSPCs 
themselves, have the capacity to undergo necroptosis in response 
to IFNα/β.
Stromal Cells
Although IFNα/β have not been directly implicated in AA 
pathogenesis, TNFα stimulates autocrine type I IFN expres-
sion in MΦs and in endothelial cells (171, 172), and could, 
therefore, establish local IFNα/β gradients in the inflamed BM 
microenvironment. Type I IFN sensing by BM stromal cells is 
not required for IFNα-induced HSPC proliferation in response 
to polyI:C, but Ifnar1−/− HSPCs are induced to proliferate in 95% 
WT: 5% Ifnar1−/− mixed BM chimeras (128), suggesting that 
IFNα/β-stimulated hematopoietic cells release additional factors 
that act on Ifnar1−/− HSPCs. HSPC-activating cues may derive 
from the HSPC pool itself, as hematopoietic progenitors produce 
a wide repertoire of inflammatory cytokines upon toll-like recep-
tor stimulation (173), or may originate from stromal niche cells 
within the BM microenvironment.
Arteriolar blood vessels and megakaryocytes comprise 
HSC niches in the BM (174–176), although they are reported 
to be spatially and functionally distinct from one another. 
Sterile, IFNα/β-driven inflammation relocates HSPCs away 
from quiescence-enforcing arteriolar niches (118), though it 
is unclear whether this is cause or consequence of changes in 
HSC cycling. IFNα/β can also stimulate endothelial chemokine 
expression, including that of CCL5 or RANTES (177), which can 
impact platelet production by megakaryocytes (178). The role of 
megakaryocytes in HSC regulation is dynamic, as homeostatic 
expression of CXCL4 and TGFβ1 promotes quiescence, while 
concomitant increases in FGF-1 and decreases in TGFβ1 facili-
tate regeneration (174, 175). To our knowledge, megakaryocyte 
dysfunction has not been investigated in the pathogenesis of 
BM failure but aberrant TGFβ1 signaling is linked to pathologic 
extracellular matrix deposition and derangement of hematopoie-
sis in myelofibrosis (179). Additionally, TGFβ slows recovery 
from chemotherapy-induced myelosuppression by blocking 
HSC proliferation (180). Since type I IFNs both impair HSCs 
and activate a program of enhanced megakaryocyte lineage 
differentiation (104), it is intriguing to consider the impact this 
may have on HSPC–niche cell interactions during recovery from 
severe IFN-driven inflammation.
CONCLUSiON
In severe AA, autoreactive T cells initiate immunopathology, 
leading to HSC depletion, and total hematopoietic collapse. IFNγ 
is well-known to correlate with AA disease severity in mice and 
humans, but the mechanisms by which IFNγ impairs HSCs remain 
somewhat elusive. The potential for IFNγ to both directly exhaust 
and deplete HSCs, as well as to indirectly reduce HSC function 
through microenvironmental niche cells, particularly macrophages, 
and MSCs (Figure 1), adds complexity to the study of AA pathogen-
esis but also reveals new potential therapeutic targets. Since type I 
IFNs have been linked to BM aplasia and sensitize HSCs to cellular 
stress (Table 1), it can be envisioned that initial IFNα/β exposure, 
as occurs in response to viral infection, may render HSCs more 
vulnerable to subsequent IFNγ-mediated impairment. Current 
understanding of how inflammatory signals impact the HSC niche 
is limited; thus, we discussed several potential mechanisms by which 
interferons may contribute indirectly to HSC loss during severe AA. 
Parallels emerge when considering the impact of IFNγ and IFNα/β 
on HSCs, including the capacity of both cytokines to (1) drive HSC 
proliferation, seemingly at the expense of long-term function; (2) 
propagate inflammatory signaling within macrophages, a critical 
HSC niche cell type; and (3) potentiate cell death through the regu-
lation of death receptor signaling, suggesting that these factors may 
be synergistically detrimental in inflammatory disease states. The 
development of additional AA mouse models, in which the inde-
pendent and concerted impact of interferon signaling on specific 
cell types can be interrogated, would be of great utility in parsing 
out the mechanisms that drive AA pathogenesis.
AUTHOR CONTRiBUTiONS
All authors listed, have made substantial, direct and intellectual 
contribution to the work, and approved it for publication.
FUNDiNG
This work was supported by R01 GM105949 to KM.
9Smith et al. IFN-Mediated BM Failure
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 330
ReFeReNCeS
1. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and clas-
sification. Autoimmun Rev (2014) 13(4–5):569–73. doi:10.1016/j.
autrev.2014.01.014 
2. Nakao S, Takami A, Takamatsu H, Zeng W, Sugimori N, Yamazaki H, et al. 
Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity 
for hematopoietic cells in a patient with aplastic anemia. Blood (1997) 
89(10):3691–9. 
3. Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. 
Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia 
and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 
spectratyping and flow cytometry. Blood (2002) 100(1):178–83. doi:10.1182/
blood-2002-01-0236 
4. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. 
Intracellular interferon-gamma in circulating and marrow T cells detected 
by flow cytometry and the response to immunosuppressive therapy in 
patients with aplastic anemia. Blood (2002) 100(4):1185–91. doi:10.1182/
blood-2002-01-0035 
5. Dufour C, Capasso M, Svahn J, Marrone A, Haupt R, Bacigalupo A, 
et  al. Homozygosis for (12) CA repeats in the first intron of the human 
IFN-gamma gene is significantly associated with the risk of aplastic 
anaemia in Caucasian population. Br J Haematol (2004) 126(5):682–5. 
doi:10.1111/j.1365-2141.2004.05102.x 
6. Mendelson A, Frenette PS. Hematopoietic stem cell niche maintenance 
during homeostasis and regeneration. Nat Med (2014) 20(8):833–46. 
doi:10.1038/nm.3647 
7. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased 
apoptosis in aplastic anemia bone marrow progenitor cells: possible patho-
physiologic significance. Exp Hematol (1995) 23(14):1642–8. 
8. Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies 
from patients with aplastic anaemia. Br J Haematol (1997) 98(1):18–20. 
doi:10.1046/j.1365-2141.1997.1532971.x 
9. Timeus F, Crescenzio N, Doria A, Foglia L, Linari A, Giaccone M, et al. Flow 
cytometric evaluation of circulating CD34+ cell counts and apoptotic rate 
in children with acquired aplastic anemia and myelodysplasia. Exp Hematol 
(2005) 33(5):597–604. doi:10.1016/j.exphem.2005.02.005 
10. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM. 
Mechanisms of bone marrow progenitor cell apoptosis in aplastic 
anaemia and the effect of anti-thymocyte globulin: examination of the 
role of the Fas-Fas-L interaction. Br J Haematol (2000) 111(4):1164–9. 
doi:10.1111/j.1365-2141.2000.02485.x 
11. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent 
haematopoietic stem cells are activated by IFN-gamma in response to chronic 
infection. Nature (2010) 465(7299):793–7. doi:10.1038/nature09135 
12. de Bruin AM, Demirel O, Hooibrink B, Brandts CH, Nolte MA. Interferon-
gamma impairs proliferation of hematopoietic stem cells in mice. Blood 
(2013) 121(18):3578–85. doi:10.1182/blood-2012-05-432906 
13. Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies 
M, et  al. Re-entry into quiescence protects hematopoietic stem cells from 
the killing effect of chronic exposure to type I interferons. J Exp Med (2014) 
211(2):245–62. doi:10.1084/jem.20131043 
14. Hamzic E, Whiting K, Gordon Smith E, Pettengell R. Characterization of 
bone marrow mesenchymal stromal cells in aplastic anaemia. Br J Haematol 
(2015) 169(6):804–13. doi:10.1111/bjh.13364 
15. Li J, Yang S, Lu S, Zhao H, Feng J, Li W, et al. Differential gene expression 
profile associated with the abnormality of bone marrow mesenchymal stem 
cells in aplastic anemia. PLoS One (2012) 7(11):e47764. doi:10.1371/journal.
pone.0047764 
16. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of 
hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. 
Proc Natl Acad Sci U S A (1985) 82(1):188–92. doi:10.1073/pnas.82.1.188 
17. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is 
up-regulated in T cells from patients with aplastic anemia. Blood (2006) 
107(10):3983–91. doi:10.1182/blood-2005-10-4201 
18. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively 
expressed in the stromal microenvironment of human marrow cultures 
mediates potent hematopoietic inhibition. Blood (1996) 87(10):4149–57. 
19. Eloranta ML, Ronnblom L. Cause and consequences of the activated 
type I interferon system in SLE. J Mol Med (Berl) (2016). doi:10.1007/
s00109-016-1421-4 
20. Banchereau J, Pascual V. Type I interferon in systemic lupus erythema-
tosus and other autoimmune diseases. Immunity (2006) 25(3):383–92. 
doi:10.1016/j.immuni.2006.08.010 
21. Lopez de Padilla CM, Niewold TB. The type I interferons: basic concepts and 
clinical relevance in immune-mediated inflammatory diseases. Gene (2016) 
576(1 Pt 1):14–21. doi:10.1016/j.gene.2015.09.058 
22. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, et al. A 
randomized phase III trial of biochemotherapy versus interferon-alpha-2b 
for adjuvant therapy in patients at high risk for melanoma recurrence. 
Melanoma Res (2009) 19(1):42–9. doi:10.1097/CMR.0b013e328314b84a 
23. Spedini P, Tajana M, Bergonzi C. Unusual presentation of hairy cell leukemia. 
Haematologica (2000) 85(5):548. 
24. Ioannou S, Hatzis G, Vlahadami I, Voulgarelis M. Aplastic anemia associated 
with interferon alpha 2a in a patient with chronic hepatitis C virus infection: 
a case report. J Med Case Reports (2010) 4:268. doi:10.1186/1752-1947-4-268 
25. King KY, Matatall KA, Shen CC, Goodell MA, Swierczek SI, Prchal JT. 
Comparative long-term effects of interferon alpha and hydroxyurea on human 
hematopoietic progenitor cells. Exp Hematol (2015) 43(10):912–918e2. 
doi:10.1016/j.exphem.2015.05.013 
26. Khan UT, Tanasescu R, Constantinescu CS. PEGylated IFNbeta-1a in the 
treatment of multiple sclerosis. Expert Opin Biol Ther (2015) 15(7):1077–84. 
doi:10.1517/14712598.2015.1053206 
27. Hezode C. Management of anaemia and other treatment complications. Dig 
Liver Dis (2013) 45(Suppl 5):S337–42. doi:10.1016/j.dld.2013.07.010 
28. Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. 
Autoimmunity (2003) 36(8):519–23. doi:10.1080/08916930310001602137 
29. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp 
Hematol (1999) 27(11):1583–92. doi:10.1016/S0301-472X(99)00109-5 
30. Aslam AK, Singh T. Aplastic anemia associated with interferon beta-1a. Am 
J Ther (2002) 9(6):522–3. doi:10.1097/00045391-200211000-00011 
31. Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient 
bone marrow aplasia: major role of interferon-alpha/beta during acute 
infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp 
Med (1997) 185(3):517–30. doi:10.1084/jem.185.3.517 
32. Mishra B, Malhotra P, Ratho RK, Singh MP, Varma S, Varma N. Human 
parvovirus B19 in patients with aplastic anemia. Am J Hematol (2005) 
79(2):166–7. doi:10.1002/ajh.20347 
33. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS. Chronic 
bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 
(1987) 317(5):287–94. doi:10.1056/NEJM198707303170506 
34. Zauli G, Capitani S. HIV-1-related mechanisms of suppression of 
CD34+ hematopoietic progenitors. Pathobiology (1996) 64(1):53–8. 
doi:10.1159/000164006 
35. Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-associated 
aplastic anemia. N Engl J Med (1997) 336(15):1059–64. doi:10.1056/
NEJM199704103361504 
36. Ahronheim GA, Auger F, Joncas JH, Ghibu F, Rivard GE, Raab-Traub N. 
Primary infection by Epstein-Barr virus presenting as aplastic anemia. N Engl 
J Med (1983) 309(5):313–4. doi:10.1056/NEJM198308043090517 
37. Sedger LM, Hou S, Osvath SR, Glaccum MB, Peschon JJ, van Rooijen N, et al. 
Bone marrow B cell apoptosis during in vivo influenza virus infection requires 
TNF-alpha and lymphotoxin-alpha. J Immunol (2002) 169(11):6193–201. 
doi:10.4049/jimmunol.169.11.6193 
38. Dumler JS. Anaplasma and Ehrlichia infection. Ann N Y Acad Sci (2005) 
1063:361–73. doi:10.1196/annals.1355.069 
39. Ismail N, Bloch KC, McBride JW. Human ehrlichiosis and anaplasmosis. Clin 
Lab Med (2010) 30(1):261–92. doi:10.1016/j.cll.2009.10.004 
40. Pearce CJ, Conrad ME, Nolan PE, Fishbein DB, Dawson JE. Ehrlichiosis: 
a cause of bone marrow hypoplasia in humans. Am J Hematol (1988) 
28(1):53–5. doi:10.1002/ajh.2830280111 
41. Burns S, Saylors R, Mian A. Hemophagocytic lymphohistiocytosis secondary 
to Ehrlichia chaffeensis infection: a case report. J Pediatr Hematol Oncol 
(2010) 32(4):e142–3. doi:10.1097/MPH.0b013e3181c80ab9 
42. McCabe A, Zhang Y, Thai V, Jones M, Jordan MB, MacNamara KC. 
Macrophage-lineage cells negatively regulate the hematopoietic stem cell 
10
Smith et al. IFN-Mediated BM Failure
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 330
pool in response to interferon gamma at steady state and during infection. 
Stem Cells (2015) 33(7):2294–305. doi:10.1002/stem.2040 
43. MacNamara KC, Oduro K, Martin O, Jones DD, McLaughlin M, Choi K, 
et al. Infection-induced myelopoiesis during intracellular bacterial infection 
is critically dependent upon IFN-gamma signaling. J Immunol (2011) 
186(2):1032–43. doi:10.4049/jimmunol.1001893 
44. Zhang Y, Jones M, McCabe A, Winslow GM, Avram D, Macnamara KC. 
MyD88 signaling in CD4 T cells promotes IFN-gamma production and 
hematopoietic progenitor cell expansion in response to intracellular 
bacterial infection. J Immunol (2013) 190(9):4725–35. doi:10.4049/
jimmunol.1203024 
45. Aksoy M, Dincol K, Erdem S, Akgun T, Dincol G. Details of blood changes 
in 32 patients with pancytopenia associated with long-term exposure to 
benzene. Br J Ind Med (1972) 29(1):56–64. 
46. Bloom ML, Wolk AG, Simon-Stoos KL, Bard JS, Chen J, Young NS. A mouse 
model of lymphocyte infusion-induced bone marrow failure. Exp Hematol 
(2004) 32(12):1163–72. doi:10.1016/j.exphem.2004.08.006 
47. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology 
and treatment of aplastic anemia. Blood (2006) 108(8):2509–19. doi:10.1182/
blood-2006-03-010777 
48. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood (2012) 
120(6):1185–96. doi:10.1182/blood-2011-12-274019 
49. Roderick JE, Gonzalez-Perez G, Kuksin CA, Dongre A, Roberts ER, 
Srinivasan J, et  al. Therapeutic targeting of NOTCH signaling ameliorates 
immune-mediated bone marrow failure of aplastic anemia. J Exp Med (2013) 
210(7):1311–29. doi:10.1084/jem.20112615 
50. Tong Q, He S, Xie F, Mochizuki K, Liu Y, Mochizuki I, et al. Ezh2 regulates 
transcriptional and posttranslational expression of T-bet and promotes 
Th1 cell responses mediating aplastic anemia in mice. J Immunol (2014) 
192(11):5012–22. doi:10.4049/jimmunol.1302943 
51. Lin FC, Karwan M, Saleh B, Hodge DL, Chan T, Boelte KC, et al. IFN-gamma 
causes aplastic anemia by altering hematopoietic stem/progenitor cell compo-
sition and disrupting lineage differentiation. Blood (2014) 124(25):3699–708. 
doi:10.1182/blood-2014-01-549527 
52. de Bruin AM, Voermans C, Nolte MA. Impact of interferon-gamma 
on hematopoiesis. Blood (2014) 124(16):2479–86. doi:10.1182/
blood-2014-04-568451 
53. Snoeck HW, Van Bockstaele DR, Nys G, Lenjou M, Lardon F, Haenen L, et al. 
Interferon gamma selectively inhibits very primitive CD342+CD38- and not 
more mature CD34+CD38+ human hematopoietic progenitor cells. J Exp 
Med (1994) 180(3):1177–82. doi:10.1084/jem.180.3.1177 
54. King KY, Baldridge MT, Weksberg DC, Chambers SM, Lukov GL, Wu S, 
et al. Irgm1 protects hematopoietic stem cells by negative regulation of IFN 
signaling. Blood (2011) 118(6):1525–33. doi:10.1182/blood-2011-01-328682 
55. Matatall KA, Shen CC, Challen GA, King KY. Type II interferon promotes 
differentiation of myeloid-biased hematopoietic stem cells. Stem Cells (2014) 
32(11):3023–30. doi:10.1002/stem.1799 
56. Feng CG, Weksberg DC, Taylor GA, Sher A, Goodell MA. The p47 GTPase 
Lrg-47 (Irgm1) links host defense and hematopoietic stem cell proliferation. 
Cell Stem Cell (2008) 2(1):83–9. doi:10.1016/j.stem.2007.10.007 
57. Murohashi I, Hoang T. Interferon-gamma enhances growth factor-depen-
dent proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 
(1991) 78(4):1085–95. 
58. Yang L, Dybedal I, Bryder D, Nilsson L, Sitnicka E, Sasaki Y, et al. IFN-gamma 
negatively modulates self-renewal of repopulating human hemopoietic stem 
cells. J Immunol (2005) 174(2):752–7. doi:10.4049/jimmunol.174.2.752 
59. Walter D, Lier A, Geiselhart A, Thalheimer FB, Huntscha S, Sobotta MC, et al. 
Exit from dormancy provokes DNA-damage-induced attrition in haemato-
poietic stem cells. Nature (2015) 520(7548):549–52. doi:10.1038/nature14131 
60. Chen J, Feng X, Desierto MJ, Keyvanfar K, Young NS. IFN-gamma-mediated 
hematopoietic cell destruction in murine models of immune-mediated 
bone marrow failure. Blood (2015) 126(24):2621–31. doi:10.1182/blood- 
2015-06-652453 
61. Kuter DJ. New thrombopoietic growth factors. Blood (2007) 109(11):4607–16. 
doi:10.1182/blood-2006-10-019315 
62. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. 
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. 
N Engl J Med (2012) 367(1):11–9. doi:10.1056/NEJMoa1200931 
63. Dellacasagrande J, Capo C, Raoult D, Mege JL. IFN-gamma-mediated con-
trol of Coxiella burnetii survival in monocytes: the role of cell apoptosis and 
TNF. J Immunol (1999) 162(4):2259–65. 
64. Li X, McKinstry KK, Swain SL, Dalton DK. IFN-gamma acts directly on 
activated CD4+ T cells during mycobacterial infection to promote apoptosis 
by inducing components of the intracellular apoptosis machinery and by 
inducing extracellular proapoptotic signals. J Immunol (2007) 179(2):939–49. 
doi:10.4049/jimmunol.179.2.939 
65. Belyaev NN, Brown DE, Diaz AI, Rae A, Jarra W, Thompson J, et al. Induction 
of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor critically dependent 
on IFN-gamma signaling during acute malaria. Nat Immunol (2010) 
11(6):477–85. doi:10.1038/ni.1869 
66. Schurch CM, Riether C, Ochsenbein AF. Cytotoxic CD8+ T cells stimulate 
hematopoietic progenitors by promoting cytokine release from bone marrow 
mesenchymal stromal cells. Cell Stem Cell (2014) 14(4):460–72. doi:10.1016/j.
stem.2014.01.002 
67. Whitmire JK, Tan JT, Whitton JL. Interferon-gamma acts directly on CD8+ 
T cells to increase their abundance during virus infection. J Exp Med (2005) 
201(7):1053–9. doi:10.1084/jem.20041463 
68. Pernis A, Gupta S, Gollob KJ, Garfein E, Coffman RL, Schindler C, et al. Lack 
of interferon gamma receptor beta chain and the prevention of interferon 
gamma signaling in TH1 cells. Science (1995) 269(5221):245–7. doi:10.1126/
science.7618088 
69. Bach EA, Szabo SJ, Dighe AS, Ashkenazi A, Aguet M, Murphy KM, et al. 
Ligand-induced autoregulation of IFN-gamma receptor beta chain expres-
sion in T helper cell subsets. Science (1995) 270(5239):1215–8. doi:10.1126/
science.270.5239.1215 
70. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, et al. IFN-gamma 
stimulates osteoclast formation and bone loss in  vivo via antigen-driven 
T cell activation. J Clin Invest (2007) 117(1):122–32. doi:10.1172/JCI30074 
71. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha 
induces differentiation of and bone resorption by osteoclasts. J Biol Chem 
(2000) 275(7):4858–64. doi:10.1074/jbc.275.7.4858 
72. Luther-Wyrsch A, Nissen C, Wodnar-Filipowicz A. Intracellular Fas ligand is 
elevated in T lymphocytes in severe aplastic anaemia. Br J Haematol (2001) 
114(4):884–90. doi:10.1046/j.1365-2141.2001.03026.x 
73. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and 
trafficking. Blood (2006) 108(2):426–31. doi:10.1182/blood-2006-01-0177 
74. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et  al. In 
vivo imaging of Treg cells providing immune privilege to the haematopoietic 
stem-cell niche. Nature (2011) 474(7350):216–9. doi:10.1038/nature10160 
75. Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, et  al. 
Functional characterization of CD4+ T cells in aplastic anemia. Blood (2012) 
119(9):2033–43. doi:10.1182/blood-2011-08-368308 
76. Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, 
McLornan D, et al. Deep-phenotyping of Tregs identifies an immune signa-
ture for idiopathic aplastic anemia and predicts response to treatment. Blood 
(2016). doi:10.1182/blood-2016-03-703702 
77. Takahashi R, Nishimoto S, Muto G, Sekiya T, Tamiya T, Kimura A, et  al. 
SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 
expression as well as IFN-{gamma} and IL-17A production. J Exp Med (2011) 
208(10):2055–67. doi:10.1084/jem.20110428 
78. Larkin J III, Ahmed CM, Wilson TD, Johnson HM. Regulation of interferon 
gamma signaling by suppressors of cytokine signaling and regulatory T cells. 
Front Immunol (2013) 4:469. doi:10.3389/fimmu.2013.00469 
79. Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam 
PS. Characterization of a peptide inhibitor of Janus kinase 2 that mimics sup-
pressor of cytokine signaling 1 function. J Immunol (2004) 172(12):7510–8. 
doi:10.4049/jimmunol.172.12.7510 
80. Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokine-stimulated 
immunomodulators of inflammatory bone disease. Curr Opin Rheumatol 
(2006) 18(4):427–32. doi:10.1097/01.bor.0000231913.32364.32 
81. Takayanagi H, Kim S, Taniguchi T. Signaling crosstalk between RANKL 
and interferons in osteoclast differentiation. Arthritis Res (2002) 4(Suppl 
3):S227–32. doi:10.1186/ar581 
82. Demeter J, Messer G, Schrezenmeier H. Clinical relevance of the TNF-alpha 
promoter/enhancer polymorphism in patients with aplastic anemia. Ann 
Hematol (2002) 81(10):566–9. doi:10.1007/s00277-002-0544-6 
11
Smith et al. IFN-Mediated BM Failure
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 330
83. Gidvani V, Ramkissoon S, Sloand EM, Young NS. Cytokine gene polymor-
phisms in acquired bone marrow failure. Am J Hematol (2007) 82(8):721–4. 
doi:10.1002/ajh.20881 
84. Burroughs L, Woolfrey A, Shimamura A. Shwachman-Diamond syndrome: 
a review of the clinical presentation, molecular pathogenesis, diagnosis, and 
treatment. Hematol Oncol Clin North Am (2009) 23(2):233–48. doi:10.1016/j.
hoc.2009.01.007 
85. Petryk A, Polgreen LE, Barnum JL, Zhang L, Hodges JS, Baker KS, et  al. 
Bone mineral density in children with fanconi anemia after hematopoietic 
cell transplantation. Biol Blood Marrow Transplant (2015) 21(5):894–9. 
doi:10.1016/j.bbmt.2015.01.002 
86. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et  al. 
Osteoclasts degrade endosteal components and promote mobilization of 
hematopoietic progenitor cells. Nat Med (2006) 12(6):657–64. doi:10.1038/
nm1417 
87. Romero H, Warburton C, Sanchez-Dardon J, Scorza T. Osteoclasts are 
required for hematopoietic stem and progenitor cell mobilization but not 
for stress erythropoiesis in Plasmodium chabaudi adami murine malaria. 
Mediators Inflamm (2016) 2016:3909614. doi:10.1155/2016/3909614 
88. DiGirolamo DJ, Clemens TL, Kousteni S. The skeleton as an endo-
crine organ. Nat Rev Rheumatol (2012) 8(11):674–83. doi:10.1038/
nrrheum.2012.157 
89. Li JY, Adams J, Calvi LM, Lane TF, DiPaolo R, Weitzmann MN, et al. PTH 
expands short-term murine hemopoietic stem cells through T cells. Blood 
(2012) 120(22):4352–62. doi:10.1182/blood-2012-06-438531 
90. McCabe A, MacNamara KC. Macrophages: key regulators of steady-state 
and demand-adapted hematopoiesis. Exp Hematol (2016) 44(4):213–22. 
doi:10.1016/j.exphem.2016.01.003 
91. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview 
of signals, mechanisms and functions. J Leukoc Biol (2004) 75(2):163–89. 
doi:10.1189/jlb.0603252 
92. Park M, Park CJ, Jang S, Kim DY, Lee JH, Lee JH, et al. Reduced expression 
of osteonectin and increased natural killer cells may contribute to the patho-
physiology of aplastic anemia. Appl Immunohistochem Mol Morphol (2015) 
23(2):139–45. doi:10.1097/PAI.0000000000000023 
93. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et  al. 
Tissue-resident macrophages self-maintain locally throughout adult life 
with minimal contribution from circulating monocytes. Immunity (2013) 
38(4):792–804. doi:10.1016/j.immuni.2013.04.004 
94. Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeo-
stasis. Immunity (2016) 44(3):439–49. doi:10.1016/j.immuni.2016.02.024 
95. Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, 
et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. 
Blood (2007) 109(2):661–9. doi:10.1182/blood-2005-12-023044 
96. Knospe WH, Steinberg D, Speck B. Experimental immunologically mediated 
aplastic anemia (AA) in H-2k identical, Mls (M) locus different mice. Exp 
Hematol (1983) 11(6):542–52. 
97. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, et al. Bone 
marrow macrophages maintain hematopoietic stem cell (HSC) niches and 
their depletion mobilizes HSCs. Blood (2010) 116(23):4815–28. doi:10.1182/
blood-2009-11-253534 
98. Hur J, Choi JI, Lee H, Nham P, Kim TW, Chae CW, et  al. CD82/KAI1 
maintains the dormancy of long-term hematopoietic stem cells through 
interaction with DARC-expressing macrophages. Cell Stem Cell (2016) 
18(4):508–21. doi:10.1016/j.stem.2016.01.013 
99. Ludin A, Itkin T, Gur-Cohen S, Mildner A, Shezen E, Golan K, et  al. 
Monocytes-macrophages that express alpha-smooth muscle actin preserve 
primitive hematopoietic cells in the bone marrow. Nat Immunol (2012) 
13(11):1072–82. doi:10.1038/ni.2408 
100. Zoller EE, Lykens JE, Terrell CE, Aliberti J, Filipovich AH, Henson PM, et al. 
Hemophagocytosis causes a consumptive anemia of inflammation. J Exp 
Med (2011) 208(6):1203–14. doi:10.1084/jem.20102538 
101. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol (2002) 
14(5):548–52. doi:10.1097/00002281-200209000-00012 
102. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syn-
drome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, 
pathophysiology and treatment. Genes Immun (2012) 13(4):289–98. 
doi:10.1038/gene.2012.3 
103. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: 
pathogenic and clinical diversity. Blood (2009) 113(26):6511–21. doi:10.1182/
blood-2009-01-129155 
104. Haas S, Hansson J, Klimmeck D, Loeffler D, Velten L, Uckelmann H, et al. 
Inflammation-induced emergency megakaryopoiesis driven by hemato-
poietic stem cell-like megakaryocyte progenitors. Cell Stem Cell (2015) 
17(4):422–34. doi:10.1016/j.stem.2015.07.007 
105. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early 
hematopoiesis in infection and inflammation. Blood (2012) 119(13):2991–
3002. doi:10.1182/blood-2011-12-380113 
106. Rashidi NM, Scott MK, Scherf N, Krinner A, Kalchschmidt JS, Gounaris 
K, et  al. In vivo time-lapse imaging shows diverse niche engagement by 
quiescent and naturally activated hematopoietic stem cells. Blood (2014) 
124(1):79–83. doi:10.1182/blood-2013-10-534859 
107. Chang KH, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt RG, et  al. p62 
is required for stem cell/progenitor retention through inhibition of IKK/
NF-kappaB/Ccl4 signaling at the bone marrow macrophage-osteoblast 
niche. Cell Rep (2014) 9(6):2084–97. doi:10.1016/j.celrep.2014.11.031 
108. Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, et al. Bone 
marrow mesenchymal stem and progenitor cells induce monocyte emigra-
tion in response to circulating toll-like receptor ligands. Immunity (2011) 
34(4):590–601. doi:10.1016/j.immuni.2011.02.016 
109. Chen YF, Wu ZM, Xie C, Bai S, Zhao LD. Expression level of IL-6 secreted 
by bone marrow stromal cells in mice with aplastic anemia. ISRN Hematol 
(2013) 2013:986219. doi:10.1155/2013/986219 
110. Gu Y, Hu X, Liu C, Qv X, Xu C. Interleukin (IL)-17 promotes macrophages 
to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. 
Br J Haematol (2008) 142(1):109–14. doi:10.1111/j.1365-2141.2008.07161.x 
111. Isern J, Garcia-Garcia A, Martin AM, Arranz L, Martin-Perez D, Torroja C, 
et al. The neural crest is a source of mesenchymal stem cells with specialized 
hematopoietic stem cell niche function. Elife (2014) 3:e03696. doi:10.7554/
eLife.03696 
112. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira 
SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone 
marrow niche. Nature (2010) 466(7308):829–34. doi:10.1038/nature09262 
113. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-
expressing mesenchymal stromal cells represent the main source of 
bone formed by adult bone marrow. Cell Stem Cell (2014) 15(2):154–68. 
doi:10.1016/j.stem.2014.06.008 
114. Greenbaum A, Hsu YM, Day RB, Schuettpelz LG, Christopher MJ, 
Borgerding JN, et al. CXCL12 in early mesenchymal progenitors is required 
for haematopoietic stem-cell maintenance. Nature (2013) 495(7440):227–30. 
doi:10.1038/nature11926 
115. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. 
Nat Rev Immunol (2008) 8(9):726–36. doi:10.1038/nri2395 
116. Chen X, Armstrong MA, Li G. Mesenchymal stem cells in immunoregulation. 
Immunol Cell Biol (2006) 84(5):413–21. doi:10.1111/j.1440-1711.2006.01458.x 
117. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 
(2006) 312(12):2169–79. doi:10.1016/j.yexcr.2006.03.019 
118. Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, et  al. 
Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 
(2013) 502(7473):637–43. doi:10.1038/nature12612 
119. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De Flora A, et al. T-cell 
suppression mediated by mesenchymal stem cells is deficient in patients with 
severe aplastic anemia. Exp Hematol (2005) 33(7):819–27. doi:10.1016/j.
exphem.2005.05.006 
120. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. 
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 
425(6960):841–6. doi:10.1038/nature02040 
121. Wu JY, Purton LE, Rodda SJ, Chen M, Weinstein LS, McMahon AP, et al. 
Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-
dependent signaling pathways. Proc Natl Acad Sci U S A (2008) 105(44): 
16976–81. doi:10.1073/pnas.0802898105 
122. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-
marrow adipocytes as negative regulators of the haematopoietic microenvi-
ronment. Nature (2009) 460(7252):259–63. doi:10.1038/nature08099 
123. Igarashi Y, Chosa N, Sawada S, Kondo H, Yaegashi T, Ishisaki A. VEGF-C 
and TGF-beta reciprocally regulate mesenchymal stem cell commitment 
12
Smith et al. IFN-Mediated BM Failure
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 330
to differentiation into lymphatic endothelial or osteoblastic phenotypes. 
Int J Mol Med (2016) 37(4):1005–13. doi:10.3892/ijmm.2016.2502
124. Liu Y, Berendsen AD, Jia S, Lotinun S, Baron R, Ferrara N, et al. Intracellular 
VEGF regulates the balance between osteoblast and adipocyte differentiation. 
J Clin Invest (2012) 122(9):3101–13. doi:10.1172/JCI61209 
125. Luo Y, Chen GL, Hannemann N, Ipseiz N, Kronke G, Bauerle T, et  al. 
Microbiota from obese mice regulate hematopoietic stem cell differentiation 
by altering the bone niche. Cell Metab (2015) 22(5):886–94. doi:10.1016/j.
cmet.2015.08.020 
126. Chow A, Lucas D, Hidalgo A, Mendez-Ferrer S, Hashimoto D, Scheiermann 
C, et al. Bone marrow CD169+ macrophages promote the retention of hema-
topoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp 
Med (2011) 208(2):261–71. doi:10.1084/jem.20101688 
127. Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, et al. Activation 
of the p38 mitogen-activated protein kinase mediates the suppressive effects 
of type I interferons and transforming growth factor-beta on normal hema-
topoiesis. J Biol Chem (2002) 277(10):7726–35. doi:10.1074/jbc.M106640200 
128. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, 
et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 
(2009) 458(7240):904–8. doi:10.1038/nature07815 
129. Porter SN, Cluster AS, Signer RA, Voigtmann J, Monlish DA, Schuettpelz 
LG, et  al. Pten cell autonomously modulates the hematopoietic stem cell 
response to inflammatory cytokines. Stem Cell Reports (2016) 6(6):806–14. 
doi:10.1016/j.stemcr.2016.04.008 
130. Ehninger A, Boch T, Uckelmann H, Essers MA, Mudder K, Sleckman BP, 
et  al. Posttranscriptional regulation of c-Myc expression in adult murine 
HSCs during homeostasis and interferon-alpha-induced stress response. 
Blood (2014) 123(25):3909–13. doi:10.1182/blood-2013-10-531038 
131. Pietras EM, Warr MR, Passegue E. Cell cycle regulation in hematopoietic 
stem cells. J Cell Biol (2011) 195(5):709–20. doi:10.1083/jcb.201102131 
132. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, et  al. PTEN 
maintains haematopoietic stem cells and acts in lineage choice and leukaemia 
prevention. Nature (2006) 441(7092):518–22. doi:10.1038/nature04747 
133. Prigge JR, Hoyt TR, Dobrinen E, Capecchi MR, Schmidt EE, Meissner N. 
Type I IFNs act upon hematopoietic progenitors to protect and maintain 
hematopoiesis during pneumocystis lung infection in mice. J Immunol 
(2015) 195(11):5347–57. doi:10.4049/jimmunol.1501553 
134. Taylor D, Wilkison M, Voyich J, Meissner N. Prevention of bone marrow cell 
apoptosis and regulation of hematopoiesis by type I IFNs during systemic 
responses to pneumocystis lung infection. J Immunol (2011) 186(10):5956–
67. doi:10.4049/jimmunol.1003558 
135. Hoyt TR, Dobrinen E, Kochetkova I, Meissner N. B cells modulate systemic 
responses to Pneumocystis murina lung infection and protect on-demand 
hematopoiesis via T cell-independent innate mechanisms when type I inter-
feron signaling is absent. Infect Immun (2015) 83(2):743–58. doi:10.1128/
IAI.02639-14 
136. Foudi A, Hochedlinger K, Van Buren D, Schindler JW, Jaenisch R, Carey V, 
et al. Analysis of histone 2B-GFP retention reveals slowly cycling hemato-
poietic stem cells. Nat Biotechnol (2009) 27(1):84–90. doi:10.1038/nbt.1517 
137. Sawen P, Lang S, Mandal P, Rossi DJ, Soneji S, Bryder D. Mitotic history 
reveals distinct stem cell populations and their contributions to hematopoie-
sis. Cell Rep (2016) 14(12):2809–18. doi:10.1016/j.celrep.2016.02.073 
138. Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, et al. DNA-
damage-induced type I interferon promotes senescence and inhibits stem cell 
function. Cell Rep (2015) 11(5):785–97. doi:10.1016/j.celrep.2015.03.069 
139. Li T, Zhou ZW, Ju Z, Wang ZQ. DNA damage response in hematopoietic 
stem cell ageing. Genomics Proteomics Bioinformatics (2016) 14(3):147–54. 
doi:10.1016/j.gpb.2016.04.002 
140. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et  al. 
Integration of interferon-alpha/beta signalling to p53 responses in tumour 
suppression and antiviral defence. Nature (2003) 424(6948):516–23. 
doi:10.1038/nature01850 
141. Haque SJ, Williams BR. Identification and characterization of an interferon 
(IFN)-stimulated response element-IFN-stimulated gene factor 3-indepen-
dent signaling pathway for IFN-alpha. J Biol Chem (1994) 269(30):19523–9. 
142. Bluyssen AR, Durbin JE, Levy DE. ISGF3 gamma p48, a specificity switch for 
interferon activated transcription factors. Cytokine Growth Factor Rev (1996) 
7(1):11–7. doi:10.1016/1359-6101(96)00005-6 
143. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory 
factor-2 protects quiescent hematopoietic stem cells from type I interferon- 
dependent exhaustion. Nat Med (2009) 15(6):696–700. doi:10.1038/nm.1973 
144. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib 
mesylate discontinuation in patients with chronic myelogenous leukemia 
in complete molecular remission for more than 2 years. Blood (2007) 
109(1):58–60. doi:10.1182/blood-2006-03-011239 
145. Binder D, van den Broek MF, Kagi D, Bluethmann H, Fehr J, Hengartner 
H, et al. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+  
T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp 
Med (1998) 187(11):1903–20. doi:10.1084/jem.187.11.1903 
146. Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, 
et al. Platelet-biased stem cells reside at the apex of the haematopoietic 
stem-cell hierarchy. Nature (2013) 502(7470):232–6. doi:10.1038/
nature12495 
147. Gekas C, Graf T. CD41 expression marks myeloid-biased adult hemato-
poietic stem cells and increases with age. Blood (2013) 121(22):4463–72. 
doi:10.1182/blood-2012-09-457929 
148. Kohli L, Passegue E. Surviving change: the metabolic journey of hemato-
poietic stem cells. Trends Cell Biol (2014) 24(8):479–87. doi:10.1016/j.
tcb.2014.04.001 
149. Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeosta-
sis: insights from the hematopoietic system. Cell Stem Cell (2007) 1(2):140–52. 
doi:10.1016/j.stem.2007.07.017 
150. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et  al. 
FOXO3A directs a protective autophagy program in haematopoietic stem 
cells. Nature (2013) 494(7437):323–7. doi:10.1038/nature11895 
151. Yang Q, Stevenson HL, Scott MJ, Ismail N. Type I interferon contributes to 
noncanonical inflammasome activation, mediates immunopathology, and 
impairs protective immunity during fatal infection with lipopolysaccha-
ride-negative ehrlichiae. Am J Pathol (2015) 185(2):446–61. doi:10.1016/j.
ajpath.2014.10.005 
152. Huang J, Ge M, Lu S, Shi J, Yu W, Li X, et al. Impaired autophagy in adult 
bone marrow CD34+ cells of patients with aplastic anemia: possible patho-
genic significance. PLoS One (2016) 11(3):e0149586. doi:10.1371/journal.
pone.0149586 
153. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. 
In-vivo dominant immune responses in aplastic anaemia: molecular tracking 
of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. 
Lancet (2004) 364(9431):355–64. doi:10.1016/S0140-6736(04)16724-X 
154. Mancuso G, Midiri A, Biondo C, Beninati C, Zummo S, Galbo R, et  al. 
Type I IFN signaling is crucial for host resistance against different species 
of pathogenic bacteria. J Immunol (2007) 178(5):3126–33. doi:10.4049/
jimmunol.178.5.3126 
155. Zhang Y, Thai V, McCabe A, Jones M, MacNamara KC. Type I interferons 
promote severe disease in a mouse model of lethal ehrlichiosis. Infect Immun 
(2014) 82(4):1698–709. doi:10.1128/IAI.01564-13 
156. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et  al. 
Type I interferon suppresses type II interferon-triggered human anti- 
mycobacterial responses. Science (2013) 339(6126):1448–53. doi:10.1126/
science.1233665 
157. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. 
Interferon alpha/beta-mediated inhibition and promotion of interferon 
gamma: STAT1 resolves a paradox. Nat Immunol (2000) 1(1):70–6. 
doi:10.1038/76940 
158. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I 
interferons act directly on CD8 T cells to allow clonal expansion and memory 
formation in response to viral infection. J Exp Med (2005) 202(5):637–50. 
doi:10.1084/jem.20050821 
159. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I 
interferons regulate cytolytic activity of memory CD8(+) T cells in the lung 
airways during respiratory virus challenge. Immunity (2010) 33(1):96–105. 
doi:10.1016/j.immuni.2010.06.016 
160. Hu X, Gu Y, Wang Y, Cong Y, Qu X, Xu C. Increased CD4+ and CD8+ effec-
tor memory T cells in patients with aplastic anemia. Haematologica (2009) 
94(3):428–9. doi:10.3324/haematol.13412 
161. Gattinoni L. Memory T cells officially join the stem cell club. Immunity (2014) 
41(1):7–9. doi:10.1016/j.immuni.2014.07.003 
13
Smith et al. IFN-Mediated BM Failure
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 330
162. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human 
memory T cell subset with stem cell-like properties. Nat Med (2011) 
17(10):1290–7. doi:10.1038/nm.2446 
163. Legarda D, Justus SJ, Ang RL, Rikhi N, Li W, Moran TM, et  al. CYLD 
proteolysis protects macrophages from TNF-mediated auto-necroptosis 
induced by LPS and licensed by type I IFN. Cell Rep (2016) 15(11):2449–61. 
doi:10.1016/j.celrep.2016.05.032 
164. Dufour C, Ferretti E, Bagnasco F, Burlando O, Lanciotti M, Ramenghi U, 
et  al. Changes in cytokine profile pre- and post-immunosuppression in 
acquired aplastic anemia. Haematologica (2009) 94(12):1743–7. doi:10.3324/
haematol.2009.007815 
165. Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor 
necrosis factor-alpha by bone marrow T lymphocytes is essential in causing 
bone marrow failure in patients with aplastic anemia. Eur J Haematol (2004) 
73(1):10–6. doi:10.1111/j.1600-0609.2004.00259.x 
166. Dubey S, Shukla P, Nityanand S. Expression of interferon-gamma and tumor 
necrosis factor-alpha in bone marrow T cells and their levels in bone marrow 
plasma in patients with aplastic anemia. Ann Hematol (2005) 84(9):572–7. 
doi:10.1007/s00277-005-1022-8 
167. Silke J, Rickard JA, Gerlic M. The diverse role of RIP kinases in necropto-
sis and inflammation. Nat Immunol (2015) 16(7):689–97. doi:10.1038/ 
ni.3206 
168. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. 
Nature (2015) 517(7534):311–20. doi:10.1038/nature14191 
169. Robinson N, McComb S, Mulligan R, Dudani R, Krishnan L, Sad S. Type 
I interferon induces necroptosis in macrophages during infection with 
Salmonella enterica serovar Typhimurium. Nat Immunol (2012) 13(10):954–
62. doi:10.1038/ni.2397 
170. McComb S, Cessford E, Alturki NA, Joseph J, Shutinoski B, Startek JB, et al. 
Type-I interferon signaling through ISGF3 complex is required for sustained 
Rip3 activation and necroptosis in macrophages. Proc Natl Acad Sci U S A 
(2014) 111(31):E3206–13. doi:10.1073/pnas.1407068111 
171. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an 
IRF1-dependent autocrine loop leading to sustained expression of chemok-
ines and STAT1-dependent type I interferon-response genes. Nat Immunol 
(2008) 9(4):378–87. doi:10.1038/ni1576 
172. Venkatesh D, Ernandez T, Rosetti F, Batal I, Cullere X, Luscinskas FW, et al. 
Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent 
interferon-beta autocrine signaling to promote monocyte recruitment. 
Immunity (2013) 38(5):1025–37. doi:10.1016/j.immuni.2013.01.012 
173. Zhao JL, Ma C, O’Connell RM, Mehta A, DiLoreto R, Heath JR, et  al. 
Conversion of danger signals into cytokine signals by hematopoietic stem 
and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem 
Cell (2014) 14(4):445–59. doi:10.1016/j.stem.2014.01.007 
174. Zhao M, Perry JM, Marshall H, Venkatraman A, Qian P, He XC, et  al. 
Megakaryocytes maintain homeostatic quiescence and promote post-injury 
regeneration of hematopoietic stem cells. Nat Med (2014) 20(11):1321–6. 
doi:10.1038/nm.3706 
175. Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et  al. 
Megakaryocytes regulate hematopoietic stem cell quiescence through 
CXCL4 secretion. Nat Med (2014) 20(11):1315–20. doi:10.1038/nm.3707 
176. Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe 
AP, et al. Distinct bone marrow blood vessels differentially regulate haemato-
poiesis. Nature (2016) 532(7599):323–8. doi:10.1038/nature19088 
177. Nakano M, Fujii T, Hashimoto M, Yukawa N, Yoshifuji H, Ohmura K, et al. 
Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) pro-
duction in human pulmonary vascular endothelial cells. Clin Exp Immunol 
(2012) 170(1):94–100. doi:10.1111/j.1365-2249.2012.04638.x 
178. Tamura S, Suzuki-Inoue K, Tsukiji N, Shirai T, Sasaki T, Osada M, et  al. 
Podoplanin-positive periarteriolar stromal cells promote megakaryocyte 
growth and proplatelet formation in mice by CLEC-2. Blood (2016) 127(13): 
1701–10. doi:10.1182/blood-2015-08-663708 
179. Ciaffoni F, Cassella E, Varricchio L, Massa M, Barosi G, Migliaccio AR. 
Activation of non-canonical TGF-beta1 signaling indicates an autoimmune 
mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells 
Mol Dis (2015) 54(3):234–41. doi:10.1016/j.bcmd.2014.12.005 
180. Brenet F, Kermani P, Spektor R, Rafii S, Scandura JM. TGFbeta restores 
hematopoietic homeostasis after myelosuppressive chemotherapy. J Exp Med 
(2013) 210(3):623–39. doi:10.1084/jem.20121610 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer MB and handling Editor declared their shared affiliation, and the 
handling Editor states that the process nevertheless met the standards of a fair and 
objective review.
Copyright © 2016 Smith, Kanwar and MacNamara. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
